The Penetration of Maraviroc Into the Central Nervous System in HIV-1 Infected Subjects on Stable Antiretroviral Therapy; a Phase I Pharmacokinetic Study.
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2015
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 06 Nov 2010 United Kingdom Clinical Research Network reports accrual to date changed from 40% to 80%.
- 06 Nov 2010 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 15 Dec 2009 New source identified and integrated (United Kingdom Clinical Research Network; 7781).